The platform will be used during clinical development to monitor immune responses to the tolerising vaccines. Credit: PeopleImages.com – Yuri A/Shutterstock.com.

Repertoire Immune Medicines has collaborated with Bristol Myers Squibb to develop tolerising vaccines for autoimmune diseases.

The partnership will leverage Repertoire’s DECODE platform to map the immune synapse and create targeted treatments with the expertise of Bristol Myers Squibb in developing and commercialising new immune medicines.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will develop selective, efficacious and durable treatments for patients with autoimmune diseases by resetting the immune system.

Repertoire will receive $65m upfront and could earn $1.8bn in additional payments, including development, regulatory and commercial milestones and tiered royalties.

The company will utilise its DECODE T cell receptor (TCR)-epitope discovery platform and lipid nanoparticle delivery technology to develop the tolerising vaccine development candidates.

The platform will also be used during clinical development to monitor immune responses to the tolerising vaccines in patients to provide insights into the vaccines’ pharmacodynamic effect.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Repertoire CEO Torben Straight Nissen stated: “This agreement is a recognition of the transformative power of Repertoire’s DECODE platform to discover and develop programmable T cell targeted immune medicines.

“This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease.”

Repertoire will spearhead the process up to the nomination of development candidates.

Under an exclusive worldwide licence, Bristol Myers Squibb will take charge of clinical development, regulatory affairs and the commercialisation of the vaccines globally.

Bristol Myers Squibb Immunology and Cardiovascular Thematic Research Center senior vice-president and head Francisco Ramírez-Valle stated: “Our collaboration with Repertoire aims to selectively reset the immune system, reflecting a key component of our immunology research strategy, which we believe may offer long-term benefit while mitigating unintended consequences associated with broad immune suppression.”

Earlier this month, Bristol Myers Squibb and 2seventy bio’s Abecma (idecabtagene vicleucel; ide-cel) obtained approval from the US Food and Drug Administration to treat adults with relapsed or refractory multiple myeloma.